

BEST AVAILABLE COPY

PCT/EP200.4 / 010696



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 26 OCT 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *AMBrewer*

Dated 21 June 2004

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977  
(Rule 16)

The  
Patent  
Office

THE PATENT OFFICE

24 SEP 2003

1/77  
REP03/2639673-2 D00245  
0.00-022371.6

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

24 SEP 2003

The Patent Office

Cardiff Road  
Newport  
South Wales NP10 8QQ

1.	Your reference	3-33379P1		
2.	Patent application number (The Patent Office will fill in this part)	0322371.6		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	NOVARTIS CONSUMER HEALTH SA ROUTE DE L'ETRAZ CH-1260 NYON SWITZERLAND		
	Patent ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation	SWITZERLAND	07220890001	
4.	Title of invention	Coated Tablets		
5.	Name of your agent (If you have one)	Craig McLean		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimblehurst Road Horsham, West Sussex RH12 5AB		
	Patents ADP number (if you know it)	07181522002 ✓		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
	a) any applicant named in part 3 is not an inventor, or			
	b) there is an inventor who is not named as an applicant, or			
	c) any named applicant is a corporate body.			
	(see note (d))			

BEST AVAILABLE COPY

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

4

Claim(s) 1

Abstract 1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)


Any other documents  
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



Craig McLean

24<sup>th</sup> September 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. Trevor Drew

01403 323069

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

### Coated Tablets

The present invention concerns coated tablets comprising the pharmaceutically active substance diclofenac, which tablets are characterized by a special, very beneficial coating.

Diclofenac is a widely used non-steroidal anti-inflammatory drug (NSAID), and in the context of this document the term "diclofenac" is to be understood as including diclofenac (free acid) and pharmaceutically acceptable salts thereof, e.g. diclofenac sodium, diclofenac potassium or diclofenac epolamine. In particular preferred is diclofenac K.

Diclofenac tablets with coatings are known in the art. The general purpose of a said coating is to protect the tablet core, including the active substance, against moisture, oxygen, chemical decomposition in general as well as mechanical abrasion and so to increase the stability, i.e. the shelf life, of the tablet. A polymer that is particularly well suited to form the basis of a film coating for diclofenac tablets is hydroxypropyl methylcellulose (HPMC). It is ideal in providing an effective moisture barrier and in general reduce permeability for gases. A corresponding film coated tablet comprising 12.5 mg diclofenac K is known in the art. Said film coated tablet is manufactured by first coating the tablet core with a white coating premix comprising HPMC, polyoxyethylene glycol 400, polyethylene sorbitan monooleate and titanium dioxide (as whitening dyestuff). The coated tablet core so obtained is then subjected to a second coating step with a clear coating premix comprising HPMC, polyoxyethylene glycol 400 and maltodextrin.

The downsides of said film coated diclofenac K tablet are as follows. As two coating steps have to be performed, the coating process is lengthy, rather complicated and in general difficult to perform. Moreover, an unsatisfactorily high amount of film coated tablets having defaults in their coatings, such as ridges or picking on their surface, are obtained. Thus, strict quality control is required and too many film coated tablets have to be sorted out. Furthermore, the taste of said twice coated tablet is not very pleasant due to the specific coating compositions used.

It is therefore a goal of the present invention to avoid said disadvantages and provide a diclofenac tablet with a film coating based on HPMC, which tablet can be manufactured by a

simpler process, within a shorter process time, with less defaults in coating, and which tablet is essentially tasteless.

Thus, the present invention concerns a film coated tablet comprising  
(a) a tablet core comprising diclofenac or a pharmaceutically acceptable salt thereof, and  
(b) a coating layer comprising HPMC, stearic acid and microcrystalline cellulose, which coating layer is completely enrobing the tablet core (a).

Preferably, the film coated tablet has one single coating layer (b).

More preferably, the film coated tablet consists essentially of (a) and (b) as defined hereinabove or hereinbelow. With respect to the tablet cores (a) this means, that, preferably, diclofenac is the only pharmaceutically active substance present.

Preferably, the coating layer (b) in addition comprises titanium dioxide as whitening dyestuff.

In the tablet core (a), diclofenac is typically present in an amount of 10-100 mg, preferably 10-50 mg. The coating of the present invention is particularly useful for enrobing tablet cores comprising diclofenac K. In particular, 12.5 mg of diclofenac K are used.

Preferably, the tablet core (a) comprises microcrystalline cellulose. By including microcrystalline cellulose into the composition of both the tablet core (a) and the coating layer (b), the compatibility between the core and the coating layer is enhanced. Typically, microcrystalline cellulose is present in an amount of 2-15%, preferably 5-10%, (w/w) of the tablet core composition.

In general, tablet cores (a) are composed of components well known in the art and are manufactured in a manner known per se.

Example 1: Film coated tablet comprising 12.5 mg Diclofenac K

Core composition

diclofenac K	12.5 mg
magnesium stearate	2.025 mg

povidone	4.05 mg
silica colloidal anhydrous	8.025 mg
cellulose, microcrystalline	13.5 mg
lactose monohydrate	33.45 mg
maize starch	99.75 mg

Coating composition

Mixture of HPMC, stearic acid, microcrystalline cellulose and titanium dioxide (e.g. "Sepifilm LP 770 White", company Seppic)	6.0 mg
---	--------

Tablet cores are manufactured in a manner known per se, e.g. by direct compression of the finely powdered components of the core composition. The tablet cores are coated with the coating composition in a manner known per se, namely by following the instructions of the manufacturer, Seppic, for applying said coating composition.

Comparative Example 1: Film coated tablet comprising 12.5 mg Diclofenac KCore composition

diclofenac K	12.5 mg
magnesium stearate	2.025 mg
povidone	4.05 mg
silica colloidal anhydrous	8.025 mg
cellulose, microcrystalline	13.5 mg
sodium starch glycolate	26.7 mg
lactose monohydrate	33.45 mg
maize starch	99.75 mg

Coating composition 1

Mixture of HPMC, Polyoxyethylene glycol 400 (= Macrogol 400), Polyethylene sorbitan monooleate (= Polysorbate 80) and titanium dioxide (e.g. Opadry® "White coating premix 13675", company Colorcon)	8.0 mg
--	--------

Coating composition 2

Mixture of HPMC, Macrogol 400 and maltodextrin

(e.g. Opadry® "Clear coating premix 14003", company Colorcon)

1.0 mg

Tablet cores are manufactured in a manner known per se, e.g. by direct compression of the finely powdered components of the core composition. The tablet cores are coated in a two-step coating process first by coating it with coating composition 1 and then by coating it with coating composition 2 in a manner known per se, namely by following the instructions of the manufacturer, Colorcon, for applying said two coating compositions.

Comparison between Example 1 and Comparative Example 1:

	Example 1	Comparative Example 1
Number of coatings	1	2
Mass of coating (mg/tablet)	6	9
Process time	60 min	95 min
Process issues	none	ridges, picking on tablet surface
Taste of final product	tasteless	not pleasant

The great advantages of Example 1, both with respect to a simpler and shorter process and with respect to the properties of the final product, are evident.

BEST AVAILABLE COPY

Claims

1. A film coated tablet comprising
  - (a) a tablet core comprising diclofenac or pharmaceutically acceptable salt thereof, and
  - (b) a coating layer comprising hydroxypropyl methylcellulose, stearic acid and microcrystalline cellulose, which coating layer is completely enrobing the tablet core (a).
2. A film coated tablet according to claim 1, wherein the tablet core (a) comprises diclofenac potassium.
3. A film coated tablet according to claim 2, wherein diclofenac potassium is present in an amount of 10-50 mg.
4. A film coated tablet according to claim 2, wherein diclofenac potassium is present in an amount of 12.5 mg.
5. A film coated tablet according to any one of claims 1-4, wherein the tablet core (a) comprises microcrystalline cellulose.
6. A film coated tablet according to claim 5, wherein microcrystalline cellulose is present in the tablet core (a) in an amount of 2-15% (w/w).
7. A film coated tablet according to any one of claims 1-6, wherein the coating layer (b) in addition comprises titanium dioxide.

BEST AVAILABLE COPY



Coated Tablets

Abstract of the Disclosure

The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets are characterized by a special, very beneficial coating based on hydroxypropyl methylcellulose.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

enu

PCT/EP2004/010696

